Quality Value & Lean Process Excellence Intern
Incyte
Quality Value & Lean Process Excellence Intern
Incyte
Biopharmaceutical company pursuing drug discovery.
SUMMARYBuilding on the first phase of the Cost of Non-Quality (CoNQ) project, the intern will extend and operationalise the quantification of quality-related costs and value drivers in operations, so that they are embedded in decision-making and support the value-based prioritisation of process improvement initiatives and resource optimization and allocation.
Use value stream mapping to simplify process and drive right-first-time execution.
Duties And Responsibilities
Cost of Non-Quality
Lean / Kaizen analysis of selected processes
Requirements
Disclaimer: The above statements are intended to describe the general nature and level of work performed by employees assigned to this job. They are not intended to be an exhaustive list of all duties, responsibilities, and qualifications. Management reserves the right to change or modify such duties as required. We Respect Your Privacy Learn more at: http://www.incyte.com/privacy-policy
The Incyte hiring organization processes your personal data to manage your job application in order to enter into an employment relationship with you if you are the successful candidate.
During the process, you may be asked to respond to questions that will screen out your application if you do not meet certain objective criteria required by the job. You can learn more about this process here.
You may have the right to access, delete, restrict, edit, move, or object to the use of your personal data. You may also have a right to report concerns to the authority responsible for data privacy in the country where the position is based or where you live or work.
You can learn more about Incyte’s data protection practices here. By accessing this link you can learn about the types of personal data we collect, how we use it, whether collection and processing is optional, sources of the personal data we process, how it is shared, where it is stored or transferred to, how long we keep it, and contact information for Incyte, Incyte’s data protection officer, and your supervisory authority (if applicable).
Please contact [email protected] if you have any questions or concerns or would like to exercise your rights.
#INSPIRE
Incyte develops and sells medicines by discovering and developing new drugs, focusing on diseases in inflammation, autoimmunity, and blood cancers. Its core product, Jakafi (ruxolitinib), is a JAK1/2 inhibitor approved to treat a rare blood cancer and works by blocking JAK enzymes to reduce abnormal blood cell growth. The company also expands its pipeline through research collaborations, partnerships, and acquisitions, such as the 2024 purchase of Escient Pharmaceuticals to strengthen its inflammation and autoimmune portfolio. Unlike some competitors that rely mainly on internal programs, Incyte combines in-house discovery with external collaborations and strategic deals to grow its drug candidates from early research to approved therapies. The goal is to deliver medicines that help patients with serious diseases by building a diverse, clinically validated portfolio of treatments through internal efforts and partnerships.
Explore more opportunities at Incyte